Compare NKTR to:
After Hours: 8.92 N/A (N/A) 1:30pm ET
| Last Trade: | 8.61 |
|---|---|
| Trade Time: | Nov 27 |
| Change: | |
| Prev Close: | 8.92 |
| Open: | 8.68 |
| Bid: | N/A |
| Ask: | 9.99 x 1000 |
| 1y Target Est: | 12.33 |
| Day's Range: | 8.56 - 8.81 |
|---|---|
| 52wk Range: | 3.90 - 10.64 |
| Volume: | 264,591 |
| Avg Vol (3m): | 733,974 |
| Market Cap: | 802.43M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.20 |
| Div & Yield: | N/A (N/A) |
| Fri, Nov 13 | Abbott: Brave or Stupid?at Motley Fool |
| Tue, Nov 10 | NEKTAR THERAPEUTICS FinancialsEDGAR Online Financials |
| Thu, Nov 5 | New Star Analyst Rankings for Nektar TherapeuticsStarMine |
| Thu, Nov 5 | NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly ReportEDGAR Online |
| Wed, Nov 4 | Nektar Therapeutics Financial Results Call scheduled for 5:00 pm ET todayCCBN |
| Wed, Nov 4 | NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online |
| Wed, Nov 4 | Nektar Therapeutics Reports Third Quarter 2009 Financial ResultsPR Newswire |
| Wed, Nov 4 | Q3 2009 Nektar Therapeutics Earnings Release - Time Not SuppliedCCBN |
| Thu, Oct 29 | Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial MarketsPR Newswire |
| Wed, Oct 28 | Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian CancerPR Newswire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.